The association of circulating irisin with metabolic risk factors in Chinese adults: a cross-sectional community-based study

Lizhi Tang  
Sichuan University West China Hospital

Yuzhen Tong  
Western University

Fang Zhang  
Sichuan University West China Hospital

Guilin Chen  
Sichuan University West China Hospital

Yun Cong Zhang  
University of Saskatchewan College of Medicine

John Jobin  
Sichuan University West China Hospital

Nanwei Tong  
Sichuan University West China Hospital  
https://orcid.org/0000-0002-5395-3660

Research article

Keywords: irisin, obesity, insulin resistance, myokines

Posted Date: October 15th, 2019

DOI: https://doi.org/10.21203/rs.2.13765/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on December 27th, 2019. See the published version at https://doi.org/10.1186/s12902-019-0479-8.
Abstract

Background Irisin is a myokine that leads to increased energy expenditure by stimulating the browning of white adipose tissue. We aimed to investigate the association of serum irisin levels with metabolic parameters in middle aged Chinese population. Methods The study was based on a cross-sectional analysis of data from 524 nondiabetic subjects aged 40~65. All participants were recruited from a screening survey for Metabolic Syndrome in a community in Southwest China, including 294 subjects categorized as overweight (defined as BMI $\geq 25$ kg/m$^2$) and 230 subjects as normal control (defined as $18.5 \leq$ BMI $< 25$ kg/m$^2$). Serum irisin concentration was quantified by enzyme linked immunosorbent assay (ELISA). The relationship of irisin with metabolic factors was determined by Pearson correlation. Multivariate linear regression was used to analyze the association of irisin with insulin resistance. Logistic regression was performed to assess the association of irisin with odds of overweight. Results Serum irisin levels were significantly lower in nondiabetic overweight subjects compared with control $(11.46 \pm 4.11$ vs $14.78 \pm 7.03 \mu$g/mL, $p = 0.02)$. Circulating irisin was positively correlated with quantitative insulin sensitivity check index (QUICKI, $r = 0.178$, $p = 0.045$) and triglycerides ($r = 0.149$, $p = 0.022$); while irisin was negatively correlated with waist circumference (WC, $r = -0.185$, $p = 0.037$), waist-to-hip ratio (WHR, $r = -0.176$, $p = 0.047$), fasting insulin ($r = -0.2$, $p = 0.024$), serum creatinine ($r = -0.243$, $p = 0.006$), homeostasis model assessment for insulin resistance (HOMA-IR, $r = -0.189$, $p = 0.033$). Multiple linear regression showed that irisin was inversely associated with HOMA-IR ($\beta = -0.342 \pm 0.154$, $p = 0.029$). Higher irisin was associated with decreased odds of being overweight (OR = 0.281, $\beta = -1.271$, $p = 0.024$). Conclusions We found that serum irisin levels were lower in overweight subjects. Moreover, serum irisin levels were inversely correlated with adverse metabolic parameters including WC, WHR, creatinine, HOMA-IR and fasting insulin, suggesting that irisin may play a role in obesity related insulin resistance.

Background

Obesity is dramatically on the rise and has become an epidemic globally. The prevalence of obesity-related morbidities also increased invariably as a result of it, including type 2 diabetes mellitus (T2DM), metabolic syndrome (MS), hypertension, chronic kidney disease (CKD), cardiovascular disease (CVD), heart failure and cancer$^1$. Sedentary lifestyle and high calorie intake result in excess of energy. Obesity is necessarily the consequence of a long-term imbalance between energy intake and expenditure, which result in insulin resistance and an imbalance in glucose metabolism that lead to the development of T2DM$^2,3$.

During the past decade, skeletal muscle has been identified as a secretory organ$^4$. Myokines include cytokines and other peptides produced, expressed and released by skeletal muscle that creates endocrine effects, and these myokines are responsible for the immediate and chronic benefits of exercise on metabolic diseases$^1,4$. Irisin is a recently discovered myokine, it is a cleaved membrane protein encoded by the fibronectin type III domain containing 5 (FNDC5) gene$^5$. Recent studies showed irisin can stimulate the expression uncoupling protein-1 (UCP-1), result in browning of white adipose tissue, thereby
stimulating energy expenditure. Exercise can induce expression of peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) of skeletal muscle, which promotes the expression of FNDC5, therefore stimulates the secretion of irisin. As a result, irisin is emerging as a promising therapeutic target for the treatment of obesity associated metabolic diseases.

Correlations between circulating irisin levels and adverse metabolic phenotypes have been analyzed in humans by several studies with conflicting results. Most studies showed a positive correlation between circulating irisin levels at baseline or FNDC5 mRNA expression and body mass index (BMI). However, another study found a negative association of circulating irisin with BMI, waist-to-hip ratio (WHR), and fat mass; decreased irisin concentration and FNDC5 gene expression were found in adipose tissue and muscle from patients with obesity. Moreno-Navarrete JM and coworkers reported circulating irisin levels were negatively associated with obesity and insulin resistance in men. A recent study found that irisin is inversely associated with fasting insulin level in obese Chinese adults but was not associated with BMI and waist circumference.

Therefore, the aims of our study are to evaluate the circulating serum irisin levels in overweight and control subjects and also to elucidate possible relationships of serum irisin levels with anthropometric and metabolic parameters in a population of Chinese adults.

**Methods**

### 2.1 Study participants

All participants were recruited from a screening survey for Metabolic Syndrome in Yinchao community of Chengdu, Sichuan province of China, between September and November 2011. Information about lifestyle and medications were obtained by questionnaire (alcohol, smoking, disease status and medication use); anthropometrical measurements were measured by trained physicians. 75-g oral glucose tolerance test (OGTT) was performed; subjects with T2DM and newly diagnosed T2DM were excluded. We recruited 524 nondiabetic subjects with full survey and biochemical data including 230 subjects with normal BMI (controls, defined as $18.5 \leq \text{BMI} < 25 \text{kg/m}^2$) and 294 subjects overweight (defined as $\text{BMI} \geq 25 \text{kg/m}^2$) according to WHO definition of overweight.

### 2.2 Anthropometric measurements

Body weight (BW) and height were measured and BMI (kg/m²) was calculated by dividing weight in kilogram (kg) by height in squared meters (m²). Waist circumference (WC) was measured midway between the lowest rib margin and the iliac crest at the end of expiration and hip circumference (HC) was the widest diameter around the most prominent points of hip pelvis. Waist-to-hip ratio (WHR) was calculated by dividing WC (cm) by HC (cm). Blood pressure was measured three times by a mercury sphygmomanometer at 5-min intervals after 10-min rest in seated position and the mean value was used.
2.3 Biochemical measurements

Blood samples were obtained from all participants after a 12-h overnight fasting and immediately centrifuged. Aliquots of serum and plasma were taken for analysis of the biochemical markers to be studied. Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) and serum creatinine (Scr) were measured by routine enzymatic methods. Blood glucose including fasting plasma glucose (FPG), 30-min plasma glucose (30-minPG) and 2-h glucose (2-hPG) after OGTT were measured by a glucose oxidase procedure. Glycosylated hemoglobin A1c (HbA1c, %) was measured by high performance liquid chromatography (HPLC, Bio-Rad D-10 hemoglobin A1C radiometer). Serum fasting insulin (Fins), 30-min insulin (30-minIns) and 2-h insulin (2-hIns) after OGTT were measured by ELISA kits (cobas e411, Toche Company, Switzerland). Serum irisin levels were measured by using the enzyme-linked immunosorbent assay (ELISA) kits (BioVision, Milpitas, CA), in accordance with the manufacturer’s instructions. The sensitivity of the assay was 1 ng/mL. The intra- and inter-assay coefficients of variation were 8% and 10% respectively.

Insulin resistance was estimated by the homeostasis model assessment for insulin resistance (HOMA-IR) which was calculated as fasting insulin (mU/L) x fasting glucose (mmol/L)/22.5. The quantitative insulin sensitivity check index (QUICKI) was calculated as 1/[log fasting insulin (mU/mL) + log fasting glucose(mg/dL)]

2.4 Statistical analysis

All variables were checked for normality by using Shapiro-Wilk test. Continuous variables were expressed as mean±SD. Student’s t test was used for normally distributed variables. Variables which did not fulfill the normality assumptions were log-transformed before parametric analysis. Correlation between irisin and metabolic parameters was assessed by age and sex adjusted Pearson correlation analysis. Multiple linear regression was used to assess the association of irisin with HOMA-IR. Logistic regression was applied to determine the association of irisin with odds of overweight (coded as 1), we coded controls = 0 (defined as 18.5 ≤ BMI < 25 kg/m^2), overweight = 1 (defined as BMI ≥ 25 kg/m^2). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for odds of overweight with relation to irisin. Sex, age smoking, alcohol and medication use were adjusted for regression model. Statistical analysis was performed by SAS 9.2 software (SAS Institute Inc, Cary, NC27513, USA). All tests were two-sided with p < 0.05 considered as statistically significant.

Results

3.1 Characteristics of the study population

The clinical characteristics and biochemical data of the controls and subjects with overweight are summarized in Table 1.
Compared to controls, subjects with overweight had significantly higher BW, BMI, WC, WHR, systolic blood pressure (SBP), diastolic blood pressure (DBP), TC, triglycerides, LDL-C, FPG, 30-min PG, 2-h PG, Fins, 30-min Ins, 2-h Ins, HbA1c, HOMA-IR, serum creatinine (Scr), lower HDL-C and QUICKI. Serum irisin levels were significantly lower in nondiabetic overweight subjects compared to control (11.46 ± 4.11 vs 14.78 ± 7.03 µg/mL, \( p = 0.02 \)).

**Table 1. Characteristics of the study population**

|                      | Controls (n=230) | Overweight (n=294) | \( p \) |
|----------------------|-----------------|-------------------|--------|
| Age (years)          | 56.74±8.06      | 57.14±8.86        | 0.08   |
| Height (cm)          | 160.19±7.64     | 157.61±7.85       | 0.154  |
| Weight (kg)          | 59.21±9.09      | 65.58±9.74        | <0.0001|
| BMI (kg/m\(^2\))     | 23±2.49         | 26.37±2.85        | <0.0001|
| WC (cm)              | 77.16±6.72      | 87.42±6.35        | <0.0001|
| WHR                  | 0.84±0.06       | 0.89±0.05         | <0.0001|
| SBP (mmHg)           | 115.8±16.04     | 130.89±17.58      | <0.0001|
| DBP (mmHg)           | 72.68±9.54      | 76.59±11.53       | <0.0001|
| TG (mmol/L)          | 1.48±1.21       | 1.95±1.41         | <0.0001|
| TC (mmol/L)          | 4.59±0.86       | 5.06±0.98         | <0.0001|
| HDL-C (mmol/L)       | 1.59±0.39       | 1.42±0.3          | <0.0001|
| LDL-C (mmol/L)       | 2.82±0.69       | 2.83±0.66         | 0.0038 |
| FPG (mmol/L)         | 5.16±1.05       | 5.58±1.26         | 0.0004 |
| 30-min PG (mmol/L)   | 9.19±2.38       | 10.47±2.89        | <0.0001|
| 2-h PG (mmol/L)      | 7.01±2.93       | 9±4.23            | <0.0001|
| HbA1c (%)            | 5.54±0.55       | 5.59±0.73         | 0.02   |
| Fins (mIU/mL)        | 6.25±3.96       | 9.65±5.49         | <0.0001|
| 30-min Ins (mIU/mL)  | 51.06±34.42     | 65.94±44.49       | <0.0001|
| 2-h Ins (mIU/mL)     | 37.32±27.26     | 56.36±36.42       | <0.0001|
| HOMA-IR              | 1.45±1          | 2.45±1.86         | <0.0001|
| QUICKI               | 0.31±0.05       | 0.27±0.04         | <0.0001|
| Scr (umol/L)         | 61.61±16.02     | 69.43±17.22       | <0.0001|
| Irisin (ug/mL)       | 14.78±7.03      | 11.46±4.11        | 0.02   |

BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; TG, triglycerides; TC, total cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; FPG, fasting plasma glucose; PG, plasma glucose; Fins, fasting insulin; Ins, insulin; HOMA-IR, homeostatic model for assessment of insulin resistance; QUICKI, quantitative insulin-sensitivity check index; Scr, serum creatinine.
3.2 Correlation of irisin with anthropometric and biochemical parameters

Pearson’s correlation analysis for serum irisin with metabolic parameters are shown in Table 2. Circulating irisin level was positively correlated with QUICKI \((r = 0.178, p = 0.045)\) and triglycerides \((r = 0.149, p = 0.022)\), but was negatively correlated with WC \((r = -0.185, p = 0.037)\), WHR \((r = -0.176, p = 0.047)\), Fins \((r = -0.2, p = 0.024)\), Scr \((r = -0.243, p = 0.006)\) and HOMA-IR \((r = -0.189, p = 0.033)\). Irisin was not correlated with cholesterol (TC, HDL-C and LDL-C), glucose (fasting glucose, postprandial glucose and HbA1C) and blood pressure (SBP and DBP).

Table 2. Correlation of irisin with anthropometric and metabolic parameters

|        | \(r\)   | \(p\)   |
|--------|---------|---------|
| Weight | -0.09   | 0.313   |
| BMI    | -0.124  | 0.165   |
| WC     | -0.185* | 0.037   |
| WHR    | -0.176* | 0.047   |
| SBP    | -0.087  | 0.329   |
| DBP    | 0.02    | 0.826   |
| TG     | 0.149*  | 0.022   |
| TC     | -0.026  | 0.775   |
| HDL-C  | 0.046   | 0.608   |
| LDL-C  | 0.03    | 0.736   |
| FPG    | 0.023   | 0.799   |
| 30-min PG | -0.11 | 0.215   |
| 2-h PG | -0.115  | 0.196   |
| HbA1c  | 0.038   | 0.671   |
| Fins   | -0.2*   | 0.024   |
| 30-min Ins | 0.062 | 0.49   |
| 2-h Ins | -0.108  | 0.225   |
| HOMA-IR| -0.189* | 0.033   |
| QUICKI | 0.178*  | 0.045   |
| Scr    | -0.243* | 0.006   |

BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; TG, triglycerides; TC, total cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; FPG, fasting plasma glucose; PG, plasma glucose; Fins, fasting insulin; Ins, insulin; HOMA-IR, homeostatic model for assessment of insulin resistance; QUICKI, quantitative insulin-
sensitivity check index; Scr, serum creatinine. r, Pearson correlation coefficient. *p < 0.05 is significant.

### 3.3 Multiple linear regression of irisin with HOMA-IR

Multiple linear regression was performed to assess the association of irisin with HOMA-IR (Table 3). Our results showed that irisin was negative associated with HOMA-IR (β = -0.342, p = 0.029) after adjustment of age, sex, smoking, alcohol and medication use.

| Table 3. Multiple linear regression of irisin with HOMA-IR |
|-----------------------------------------------------------|
| **β±SE of β** | **t-Value** | **p** |
| Age           | 0.014±0.006 | 2.6   | 0.01 |
| Sex           | 0.153±0.113 | 1.35  | 0.181|
| BMI           | 0.063±0.016 | 3.93  | 0.0002|
| Irisin        | -0.342±0.154| -2.22 | 0.029|

Sex, age smoking, alcohol and medication use were adjusted for model. BMI, body mass index; β, regression coefficient; SE, standard error; *p < 0.05 is significant.

### 3.4 Multivariate logistic regression analysis of irisin with odds of overweight

In order to analyze the association of irisin with odds of overweight, logistic regression was performed. We coded overweight = 1 (BM ≥ 25kg/m²) and normal controls = 0 (18.5 ≤ BMI < 25 kg/m²) as shown in Table 4. Higher level of irisin was significantly associated with decreased odds of overweight with odds ratio of 0.281 (β = -1.271, 95% CI: 0.093 ~ 0.851, p = 0.024).

| Table 4. Logistic regression analysis of irisin with odds of overweight |
|---------------------------------------------------------------|
| **β** | **OR** | **95%CI** | **p** |
| Model: Overweight (BMI≥25kg/m²) = 1, Controls = 0 |
| Age    | 0.035  | 1.035   | (0.99~1.083) | 0.132 |
| Sex    | -1.421 | 0.242   | (0.106~0.548) | 0.000 |
| Irisin | -1.271 | 0.281   | (0.093~0.851) | 0.024 |

Age, sex, smoking, alcohol and medication use were adjusted. β, regression coefficient; OR, odds ratio; 95% CI, 95% confidence interval, *p < 0.05 is significant.
Discussion

In the present study, we found that serum irisin levels were significantly lower in overweight subjects compared to controls in middle aged Chinese. Circulating irisin concentration was negatively correlated with adverse metabolic parameters including WC, WHR, fasting insulin, HOMA-IR and serum creatinine. Moreover, multiple linear regression revealed that irisin was significant in an inverse relationship with HOMA-IR. In addition, logistic regression showed that higher irisin was associated with decreased odds of overweight.

In accordance with our finding, Liu et al. also reported decreased irisin level in obese Han Chinese. Several studies have implicated the role of PGC-1α in pathogenesis of obesity and T2DM. Moreover, PGC-1α expression and its activity were significantly down-regulated in skeletal muscles in patients with obesity and T2DM. Irisin was discovered as a PGC-1α activated messenger of myocytes that linked physical inactivity, obesity and diabetes. Thus, it is possible that lower levels of irisin in overweight observed in our study might be caused by impaired PGC-1α expression and functions in their muscle tissues.

In study conducted in patients with insulin resistance, irisin levels were determined to increase with the insulin resistance and decrease as insulin sensitivity increases. On the contrary, we found a significant negative correlation of irisin with fasting insulin and HOMA-IR, positive correlation with insulin sensitivity index QUICKI. In agreement with our findings, Yan and coworkers showed that irisin was negatively associated with fasting insulin in a large Chinese population with MS. Another study by Shi et al. showed that elevated circulating irisin was associated with lower risk of insulin resistance indirectly through lowering fasting insulin in obesity. Shanaki M et al. also found that irisin was negatively correlated with HOMA-IR and insulin in patients with nonalcoholic fatty liver disease (NAFLD). A recent study showed a negative correlation of HOMA-IR with circulating irisin levels in young girls suggesting that irisin secretion at an early age might delay the onset of obesity, insulin resistance and T2DM. In our study, the negative correlation of irisin with markers of insulin resistance indicated that decreased irisin expression in response to decreasing insulin sensitivity and disturbance in metabolisms associated with obesity.

On the contrary, a study revealed that irisin was positively associated with markers of insulin resistance including HOMA-IR. Serum levels of irisin were positively associated with blood glucose levels and fasting insulin in healthy individuals, and in those with obesity but not T2DM in children and in women with polycystic ovary syndrome. A meta-analysis revealed that irisin concentration was positively associated with insulin resistance in adults who do not have T2DM. The negative association between irisin and HOMA-IR observed in our study could be secondary results of impaired PGC-1α function in obesity. As we know, PGC-1α can stimulate the expression of irisin, which is induced by exercise and exerts profound activity in the WAT, stimulating browning of WAT and UCP1 expression. Importantly, this...
causes a significant increase in total body energy expenditure and resistance to obesity-linked insulin resistance.

Different types of diabetes may have different levels of irisin. The levels of irisin in type 1 diabetes are not fully defined yet, one study showed the level of irisin in patients with type 1 diabetes was higher than control, while another study showed opposite results. Most studies have shown that irisin levels were lower in patients with T2DM. A meta-analysis of 1289 patients with T2DM and 834 controls showed lower irisin in patients with T2DM. It is possible to conclude that irisin hormone is not only associated with exercise but also with hormones, insulin resistance, inflammation and autoimmunity.

Current study on irisin concentrations and adiposity parameters remains controversial. In accordance with our findings, some studies found a significant negative correlation of circulating irisin with WC and WHR in nondiabetic individuals. However, contradictory to our results most studies have revealed a positive correlation of serum irisin levels with BMI and WC in nondiabetic individuals. Van Marken Lichtenbelt et al showed that the amount of BAT was significantly decreased in association with obesity, with a negative linear relationship between BAT, BMI and percent body fat. Although we found there was no association between irisin and BMI; Pearson correlation showed that irisin was inversely associated with WC and WHR; suggesting abdominal obesity could be a link between decreased irisin and insulin resistance.

A population-based cohort included 967 non-diabetic people living in Germany, this study investigated the association between irisin and lipid levels, finding a significant association with favorable lipid profile; in particular, an inverse association of irisin with total cholesterol concentration. Buscemi S, et al also found a positive association between HDL-cholesterol concentrations and irisin concentration. However, we found a positive association between irisin and triglycerides, no association with total cholesterol or HDL-C.

We also found that irisin was negatively correlated with serum creatinine. Accordingly, Ates I et al. showed irisin was negatively associated with serum creatinine among patients with type 1 diabetes. A previous study conducted in patients with chronic renal failure, irisin levels were determined to be negatively correlated with creatinine, which is considered to result from the inhibition of FNDC5 by indoxyl sulphate which is a uremic toxin. The negative association between irisin and creatine suggest that creatinine may have a role in the pathophysiology of irisin or vice versa. Further studies are needed to uncover the possible underlying mechanism for this.

We do have some limitations in this study. Firstly, the cross-sectional study design was unable to provide information on prospective changes in each metabolic parameter and their association with irisin. Secondly, our sample size was relatively small, therefore we did not further sub-divide overweight patients by obesity level. So the conclusion should only be generalized to overweight rather than different grade of obesity. Moreover, there has been controversies regarding available irisin ELISA kits, including antibody specificity of antibody, its cross-reactivity with FNDC5 and the wide range of irisin levels between
different studies\textsuperscript{35,37}. In addition, different ethnicity and lifestyle may have different results; generalization beyond Asian populations should be interpreted with caution.

**Conclusions**

We found that serum irisin levels were decreased in overweight, which was presumably related to impaired muscle PGC-1\(\alpha\) expression or dysfunction among these subjects. Moreover, serum irisin level was negatively associated to HOMA-IR and fasting insulin, suggesting that irisin may play a role in obesity related insulin resistance. Thus, modification of circulating irisin level may help in the management of obesity and related metabolic diseases. However, further studies are needed to deepen in several aspects of irisin secretion and metabolism in order to clarify its full potential as a meaningful drug target in human disease states.

**Declarations**

**Acknowledgment:** not applicable.

**Contributors:** All the authors engaged in the surveys. LZT and NWT designed this article. LDT, YZT, FZ and GLC acquired and collected the data. LTZ, YZT, JJ and YCZ organized all the data. LDT and YZT analyzed all the information. LZT and YZT drafted the manuscript. LZT and NWT revised the article critically. All the authors read and approved the final manuscript.

**Funding resources:** this study was supported by Science and Technology Department of Sichuan Province, Young Teachers Funding of Sichuan University and National Natural Science Foundation of China (Grant No.81700740, 2017JY0268 and 2017SCU11028)

**Conflicts of interest disclosures** All of the authors declare that there are no conflicts of interest.

**Consent for publication:** Not Applicable.

**Availability of data and materials:** The datasets supporting the conclusions of this research are included within the article.

**Ethics approval:** This study was approved by the Medical Ethics Committee of West China Hospital of Sichuan University and was conducted in accordance with the principles of the Declaration of Helsinki II. Written informed consents were obtained from all participants.

**References**

1. Shoukry A, Shalaby SM, El-Arabi Bdeer S, Mahmoud AA, Mousa MM, Khalifa A. Circulating serum irisin levels in obesity and type 2 diabetes mellitus. IUBMB life. Jul 2016;68(7):544-556.
2. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. Jama. Jan 1 2003;289(1):76-79.

3. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. The Journal of clinical investigation. Jul 2006;116(7):1793-1801.

4. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nature reviews. Endocrinology. Apr 3 2012;8(8):457-465.

5. Martinez Munoz IY, Camarillo Romero EDS, Garduno Garcia JJ. Irisin a Novel Metabolic Biomarker: Present Knowledge and Future Directions. International journal of endocrinology. 2018;2018:7816806.

6. Arhine LI, Mihalache L, Covasa M. Irisin: A Hope in Understanding and Managing Obesity and Metabolic Syndrome. Frontiers in endocrinology. 2019;10:524.

7. Bostrom P, Wu J, Jedrychowski MP, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. Jan 11 2012;481(7382):463-468.

8. Perakakis N, Triantafyllou GA, Fernandez-Real JM, et al. Physiology and role of irisin in glucose homeostasis. Nature reviews. Endocrinology. Jun 2017;13(6):324-337.

9. Huh JY, Panagiotou G, Mougiou V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism: clinical and experimental. Dec 2012;61(12):1725-1738.

10. Park KH, Zaichenko L, Brinkoetter M, et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. The Journal of clinical endocrinology and metabolism. Dec 2013;98(12):4899-4907.

11. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity--correlation with body mass index. Peptides. Jan 2013;39:125-130.

12. Moreno M, Moreno-Navarrete JM, Serrano M, et al. Circulating irisin levels are positively associated with metabolic risk factors in sedentary subjects. PloS one. 2015;10(4):e0124100.

13. Shi X, Lin M, Liu C, et al. Elevated circulating irisin is associated with lower risk of insulin resistance: association and path analyses of obese Chinese adults. BMC endocrine disorders. Jul 29 2016;16(1):44.

14. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. The Journal of clinical endocrinology and metabolism. Apr 2013;98(4):E769-778.

15. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (London, England). Jan 10 2004;363(9403):157-163.

16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. Jul 1985;28(7):412-419.
17. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. The Journal of clinical endocrinology and metabolism. Jul 2000;85(7):2402-2410.

18. Liu BW, Yin FZ, Qi XM, Fan DM, Zhang Y. The Levels of Serum Irisin as a Predictor of Insulin Resistance in Han Chinese Adults with Metabolically Healthy Obesity. Clinical laboratory. May 1 2017;63(5):881-886.

19. Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Advances in physiology education. Dec 2006;30(4):145-151.

20. Soyal S, Krempler F, Oberkofler H, Patsch W. PGC-1alpha: a potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes. Diabetologia. Jul 2006;49(7):1477-1488.

21. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature genetics. Jul 2003;34(3):267-273.

22. Sesti G, Andreozzi F, Fiorentino TV, et al. High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta diabetologica. Oct 2014;51(5):705-713.

23. Yan B, Shi X, Zhang H, et al. Association of serum irisin with metabolic syndrome in obese Chinese adults. PloS one. 2014;9(4):e94235.

24. Shanaki M, Moradi N, Emamgholipour S, Fadaei R, Poustchi H. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes & metabolic syndrome. Nov 2017;11 Suppl 1:S467-S472.

25. Al-Daghri NM, Alkharfy KM, Rahman S, et al. Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects. European journal of clinical investigation. Feb 2014;44(2):119-124.

26. Reinehr T, Elfers C, Lass N, Roth CL. Irisin and its relation to insulin resistance and puberty in obese children: a longitudinal analysis. The Journal of clinical endocrinology and metabolism. May 2015;100(5):2123-2130.

27. Qiu S, Cai X, Yin H, et al. Association between circulating irisin and insulin resistance in non-diabetic adults: A meta-analysis. Metabolism: clinical and experimental. Jun 2016;65(6):825-834.

28. Ates I, Arikan MF, Erdogan K, et al. Factors associated with increased irisin levels in the type 1 diabetes mellitus. Endocrine regulations. Jan 1 2017;51(1):1-7.

29. Tentolouris A, Eleftheriadou I, Tsilingiris D, et al. Plasma Irisin Levels in Subjects with Type 1 Diabetes: Comparison with Healthy Controls. Hormone and metabolic research. Nov 2018;50(11):803-810.

30. Liu JJ, Wong MD, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. Journal of diabetes and its complications. Jul-Aug 2013;27(4):365-369.

31. Du XL, Jiang WX, Lv ZT. Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Hormone and metabolic research. Sep 2016;48(10):644-652.
32. Polyzos SA, Anastasilakis AD, Efstathiadou ZA, et al. Irisin in metabolic diseases. Endocrine. Feb 2018;59(2):260-274.

33. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al. Cold-activated brown adipose tissue in healthy men. The New England journal of medicine. Apr 9 2009;360(15):1500-1508.

34. Oelmann S, Nauck M, Volzke H, Bahls M, Friedrich N. Circulating Irisin Concentrations Are Associated with a Favourable Lipid Profile in the General Population. PloS one. 2016;11(4):e0154319.

35. Buscemi S, Corleo D, Vasto S, et al. Factors associated with circulating concentrations of irisin in the general population cohort of the ABCD study. International journal of obesity (2005). Mar 2018;42(3):398-404.

36. Wen MS, Wang CY, Lin SL, Hung KC. Decrease in irisin in patients with chronic kidney disease. PloS one. 2013;8(5):e64025.

37. Erickson HP. Irisin and FNDC5 in retrospect: An exercise hormone or a transmembrane receptor? Adipocyte. Oct 1 2013;2(4):289-293.